News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Participation at Upcoming Investor and Industry Conferences
Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023:
Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio
Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.
Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
Flamingo Therapeutics Announces Appointment of Andrew E. Denker, MD, PhD, as Chief Medical Officer
Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
Flamingo Therapeutics to Present at the BioEquity Europe and Knowledge for Growth Conferences in May 2022
Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company ...
Media
Can Cancer Be Treated by Changing Its Cells?
In 2017, Karen Kostroff, a renowned oncology surgeon at Northwell Health in the New York Metropolitan area added a new talking point ...
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Flamingo Therapeutics was born out of a collaboration between three partners in Flanders – VIB, UGent and KU Leuven – and the University of Michigan ...
Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...